Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients

NCT01747837 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this trial is to determine the efficacy and safety of adjunctive catheter-based renal sympathetic denervation (RSDN) in the primary prevention of implantable cardioverter defibrillator (ICD) therapy in patients with ischemic or non-ischemic ventricular dysfunction, who are to receive an ICD for either i) secondary prevention, or ii) primary prevention + inducible ventricular tachycardia (VT) by programmed ventricular stimulation at the time of ICD implantation. These patients will be randomized to ICD alone or ICD + RSDN.

Conditions Studied

Interventions

  • DEVICE Boston Scientific Vessix Renal Denervation System

Study Locations (4)

Other

  • Na Homolce Hospital — Prague
  • Academician E.N. Meshalkin Novosibirsk State Budget Research Institute of Circulation Pathology — Novosibirsk

New York

  • Mount Sinai Hospital — New York

Texas

  • Texas Cardiac — Austin

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2015-10-22
Est. Completion 2019-01-09
Phase NA

Sponsor

Vivek Reddy

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01747837

The ClinicalTrials.gov registry entry for NCT01747837 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vivek Reddy, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention — of which Boston Scientific Vessix Renal Denervation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01747837 reports 4 study locations spanning 3 distinct geographic areas — top geographies include Other, New York, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01747837 about?

NCT01747837 is a clinical study titled "REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients". The objective of this trial is to determine the efficacy and safety of adjunctive catheter-based renal sympathetic denervation (RSDN) in the primary prevention of implantable cardioverter defibrillator (ICD) therapy in patients with ischemic or non-ischemic ventricular dysfunction, who are to receiv...

What is the current status of trial NCT01747837?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2015-10-22. Estimated completion is 2019-01-09.

What conditions does trial NCT01747837 study?

This clinical trial studies the following conditions: Ventricular Tachycardia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01747837?

The interventions under investigation include: Boston Scientific Vessix Renal Denervation System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01747837?

This trial is sponsored by Vivek Reddy, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01747837 being conducted?

This trial has 4 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial